BiotechTube

IMI/REL FDC + PIP/TAZ FDC + Linezolid

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hospital-Acquired Bacterial Pneumonia

Conditions

Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia

Trial Timeline

Sep 18, 2018 → Jul 12, 2022

NCT ID
NCT03583333

About IMI/REL FDC + PIP/TAZ FDC + Linezolid

IMI/REL FDC + PIP/TAZ FDC + Linezolid is a phase 3 stage product being developed by Merck for Hospital-Acquired Bacterial Pneumonia. The current trial status is completed. This product is registered under clinical trial identifier NCT03583333. Target conditions include Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia.

What happened to similar drugs?

1 of 1 similar drugs in Hospital-Acquired Bacterial Pneumonia were approved

Approved (1) Terminated (0) Active (0)
✅Zavicefta, Ceftazidime-AvibactamPfizerApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03583333Phase 3Completed

Competing Products

2 competing products in Hospital-Acquired Bacterial Pneumonia

See all competitors
ProductCompanyStageHype Score
HRS-8427 + MeropenemJiangsu Hengrui MedicinePhase 2
42
Zavicefta, Ceftazidime-AvibactamPfizerApproved
43